During ACR Convergence 2020, Jinoos Yazdany, MD, MPH, discussed innovative research into a potential treatment for lupus, medication tapering & more. These findings may influence the treatment of rheumatic disease in the future.
ACR CONVERGENCE 2020—In her ARP keynote address on Friday, Nov. 6, Empowering Patients to Make an Impact on the Future of Healthcare, Jen Horonjeff, PhD, described a study in which researchers gathered data on pain and activity level among arthritis patients. In her view, the study provided a cautionary tale. Researchers expected the study subjects…
As the COVID-19 pandemic stretches on, many clinicians are thinking about the lessons they’ve learned. Chris Phillips, MD, says rheumatology practices can no longer take their financial health for granted and flexibility is key.
In rural America, where rheumatology offices are fewer and farther between, the expansion of telemedicine has been a boon during the COVID-19 pandemic. However, lab closures and reduced hospital services have made monitoring patients’ medications more challenging.
The Global Rheumatology Alliance is an important tool for assessing COVID-19 risk, & the ACR COVID-19 Task Force provides treatment guidance to rheumatology practitioners.
Immune checkpoint inhibitors effectively treat malignancy in ways that were not possible just a few years ago, but immune-related adverse events are a potential side effect.